Krystal Biotech, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Krystal Biotech, Inc. (KRYS) reported Cash and Cash Equivalents, Period Increase (Decrease) of $104.16 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-07.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-08-07
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-06-30 was $111.45M, a 25.83% increase year-over-year.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2020-03-31 was -$7.29M.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was -$7.29M, a 112.79% decline year-over-year.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $8.22M, a 69.32% increase year-over-year.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $83.84M, a 55.04% increase from fiscal 2018.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $54.08M, a 13.45% increase from fiscal 2017.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $47.67M, a 2378.84% increase from fiscal 2016.
- Krystal Biotech, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.92M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2020-06-30 | $111.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $104.16M 10-Q · filed 2020-08-07 | $96.87M derived: sum of 3 quarters · filed 2020-08-07 | $105.09M derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | -$7.29M 10-Q · filed 2020-05-04 | -$14.58M derived: sum of 2 quarters · filed 2020-05-04 | -$6.36M derived: sum of 3 quarters · filed 2020-05-04 | $82.21M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-12-31 | -$7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $927.00K derived: sum of 2 quarters · filed 2020-03-10 | $89.50M derived: sum of 3 quarters · filed 2020-08-07 | $83.84M 10-K · filed 2020-03-10 |
| 2019-09-30 | $8.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $96.79M derived: sum of 2 quarters · filed 2020-08-07 | $91.14M 10-Q · filed 2019-11-04 | $148.14M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-06-30 | $88.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $82.92M 10-Q · filed 2020-08-07 | $139.92M derived: sum of 3 quarters · filed 2020-08-07 | $144.77M derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | -$5.66M 10-Q · filed 2020-05-04 | $51.35M derived: sum of 2 quarters · filed 2020-05-04 | $56.20M derived: sum of 3 quarters · filed 2020-05-04 | $50.78M derived: sum of 4 quarters · filed 2020-05-04 |
| 2018-12-31 | $57.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $61.86M derived: sum of 2 quarters · filed 2020-03-10 | $56.44M derived: sum of 3 quarters · filed 2020-03-10 | $54.08M 10-K · filed 2020-03-10 |
| 2018-09-30 | $4.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$561.00K derived: sum of 2 quarters · filed 2019-11-04 | -$2.92M 10-Q · filed 2019-11-04 | -$5.90M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$5.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$7.78M 10-Q · filed 2019-08-05 | -$10.76M derived: sum of 3 quarters · filed 2019-08-05 | $38.30M derived: sum of 4 quarters · filed 2019-08-05 |
| 2018-03-31 | -$2.36M 10-Q · filed 2019-05-07 | -$5.34M derived: sum of 2 quarters · filed 2019-05-07 | $43.71M derived: sum of 3 quarters · filed 2019-05-07 | $45.27M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | -$2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $46.07M derived: sum of 2 quarters · filed 2018-11-05 | $47.63M derived: sum of 3 quarters · filed 2018-11-05 | $47.67M 10-K · filed 2018-03-12 |
| 2017-09-30 | $49.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $50.61M derived: sum of 2 quarters · filed 2018-11-05 | $50.65M 10-Q · filed 2018-11-05 | $52.17M derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $1.59M 10-Q · filed 2018-08-06 | $3.12M derived: sum of 3 quarters · filed 2018-08-06 | |
| 2017-03-31 | $36.00K 10-Q · filed 2018-05-07 | $1.56M derived: sum of 2 quarters · filed 2018-05-07 | ||
| 2016-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $1.92M 10-K · filed 2018-03-12 | ||
| 2016-09-30 | $398.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |